Ependymoma natural history: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(Mahshid)
 
(8 intermediate revisions by one other user not shown)
Line 3: Line 3:
{{CMG}} {{AE}} {{AAM}}
{{CMG}} {{AE}} {{AAM}}
==Overview==
==Overview==
If left untreated, patients with ependymoma may progress to develop [[nausea]], [[vomiting]], [[headache]], and [[irritability]]. Common complications of ependymoma include [[seizure]], [[hydrocephalus]], [[paralysis|muscle paralysis]], and [[speech problems]].
==Complication==
==Complication==
Common complications associated with ependymomas are:
Common complications associated with ependymomas are:
Line 11: Line 12:
*[[Speech problems]]
*[[Speech problems]]
*[[paralysis|Muscle paralysis]]
*[[paralysis|Muscle paralysis]]
==Prognosis==
==Prognosis==
Unfavorable factors affecting outcome include the following:<ref name=Cancergove> Eoendymoma. http://www.cancer.gov/types/brain/hp/child-ependymoma-treatment-pdq#section/_35 URL Accessed on 10 6 2015.</ref>
Unfavorable factors affecting outcome include the following:<ref name=Cancergove> Eoendymoma. http://www.cancer.gov/types/brain/hp/child-ependymoma-treatment-pdq#section/_35 URL Accessed on 10 6 2015.</ref>


*Gain of ''chromosome 1q25'' is present in approximately 20% of pediatric intracranial ependymoma cases and has been reported as a negative [[prognostic|prognostic factor]] by multiple research groups.<ref name="pmid22526017">{{cite journal| author=Godfraind C, Kaczmarska JM, Kocak M, Dalton J, Wright KD, Sanford RA et al.| title=Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas. | journal=Acta Neuropathol | year= 2012 | volume= 124 | issue= 2 | pages= 247-57 | pmid=22526017 | doi=10.1007/s00401-012-0981-9 | pmc=PMC3554251 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22526017  }} </ref><ref name="pmid16609018">{{cite journal| author=Mendrzyk F, Korshunov A, Benner A, Toedt G, Pfister S, Radlwimmer B et al.| title=Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. | journal=Clin Cancer Res | year= 2006 | volume= 12 | issue= 7 Pt 1 | pages= 2070-9 | pmid=16609018 | doi=10.1158/1078-0432.CCR-05-2363 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16609018  }} </ref>
*Gain of ''chromosome 1q25'' is present in approximately 20% of pediatric intracranial ependymoma cases and has been reported as a negative [[prognostic|prognostic factor]] by multiple research groups.<ref name="pmid22526017">{{cite journal| author=Godfraind C, Kaczmarska JM, Kocak M, Dalton J, Wright KD, Sanford RA et al.| title=Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas. | journal=Acta Neuropathol | year= 2012 | volume= 124 | issue= 2 | pages= 247-57 | pmid=22526017 | doi=10.1007/s00401-012-0981-9 | pmc=PMC3554251 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22526017  }} </ref><ref name="pmid16609018">{{cite journal| author=Mendrzyk F, Korshunov A, Benner A, Toedt G, Pfister S, Radlwimmer B et al.| title=Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. | journal=Clin Cancer Res | year= 2006 | volume= 12 | issue= 7 Pt 1 | pages= 2070-9 | pmid=16609018 | doi=10.1158/1078-0432.CCR-05-2363 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16609018  }} </ref>
*[[Gene expression]] profile.<ref name="pmid22322993">{{cite journal| author=Wani K, Armstrong TS, Vera-Bolanos E, Raghunathan A, Ellison D, Gilbertson R et al.| title=A prognostic gene expression signature in infratentorial ependymoma. | journal=Acta Neuropathol | year= 2012 | volume= 123 | issue= 5 | pages= 727-38 | pmid=22322993 | doi=10.1007/s00401-012-0941-4 | pmc=PMC4013829 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22322993  }} </ref>
*[[Gene expression]] profile<ref name="pmid22322993">{{cite journal| author=Wani K, Armstrong TS, Vera-Bolanos E, Raghunathan A, Ellison D, Gilbertson R et al.| title=A prognostic gene expression signature in infratentorial ependymoma. | journal=Acta Neuropathol | year= 2012 | volume= 123 | issue= 5 | pages= 727-38 | pmid=22322993 | doi=10.1007/s00401-012-0941-4 | pmc=PMC4013829 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22322993  }} </ref>


*Other factors that have been reported to be associated with poor prognosis for pediatric ependymoma include expression of the enzymatic subunit of [[telomerase]] (hTERT) and expression of the neural stem cell marker Nestin.<ref name="pmid16575002">{{cite journal| author=Tabori U, Ma J, Carter M, Zielenska M, Rutka J, Bouffet E et al.| title=Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma. | journal=J Clin Oncol | year= 2006 | volume= 24 | issue= 10 | pages= 1522-8 | pmid=16575002 | doi=10.1200/JCO.2005.04.2127 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16575002  }} </ref><ref name="pmid23076205">{{cite journal| author=Modena P, Buttarelli FR, Miceli R, Piccinin E, Baldi C, Antonelli M et al.| title=Predictors of outcome in an AIEOP series of childhood ependymomas: a multifactorial analysis. | journal=Neuro Oncol | year= 2012 | volume= 14 | issue= 11 | pages= 1346-56 | pmid=23076205 | doi=10.1093/neuonc/nos245 | pmc=PMC3480268 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23076205  }} </ref>
*Other factors that have been reported to be associated with poor prognosis for pediatric ependymoma include expression of the enzymatic subunit of [[telomerase]] (hTERT) and expression of the neural stem cell marker Nestin.<ref name="pmid16575002">{{cite journal| author=Tabori U, Ma J, Carter M, Zielenska M, Rutka J, Bouffet E et al.| title=Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma. | journal=J Clin Oncol | year= 2006 | volume= 24 | issue= 10 | pages= 1522-8 | pmid=16575002 | doi=10.1200/JCO.2005.04.2127 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16575002  }} </ref><ref name="pmid23076205">{{cite journal| author=Modena P, Buttarelli FR, Miceli R, Piccinin E, Baldi C, Antonelli M et al.| title=Predictors of outcome in an AIEOP series of childhood ependymomas: a multifactorial analysis. | journal=Neuro Oncol | year= 2012 | volume= 14 | issue= 11 | pages= 1346-56 | pmid=23076205 | doi=10.1093/neuonc/nos245 | pmc=PMC3480268 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23076205  }} </ref>
Line 22: Line 22:
*Tumor location. Cranial variants of ependymoma have a less favorable outcome than primary [[spinal cord]] ependymomas. Location within the spinal cord may also affect outcome, with tumors in the lower portion of the spinal cord having a worse prognosis.<ref name="pmid23259510">{{cite journal| author=Oh MC, Sayegh ET, Safaee M, Sun MZ, Kaur G, Kim JM et al.| title=Prognosis by tumor location for pediatric spinal cord ependymomas. | journal=J Neurosurg Pediatr | year= 2013 | volume= 11 | issue= 3 | pages= 282-8 | pmid=23259510 | doi=10.3171/2012.11.PEDS12292 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23259510  }} </ref>
*Tumor location. Cranial variants of ependymoma have a less favorable outcome than primary [[spinal cord]] ependymomas. Location within the spinal cord may also affect outcome, with tumors in the lower portion of the spinal cord having a worse prognosis.<ref name="pmid23259510">{{cite journal| author=Oh MC, Sayegh ET, Safaee M, Sun MZ, Kaur G, Kim JM et al.| title=Prognosis by tumor location for pediatric spinal cord ependymomas. | journal=J Neurosurg Pediatr | year= 2013 | volume= 11 | issue= 3 | pages= 282-8 | pmid=23259510 | doi=10.3171/2012.11.PEDS12292 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23259510  }} </ref>
*Younger age at diagnosis.<ref name="pmid19387655">{{cite journal| author=Tamburrini G, D'Ercole M, Pettorini BL, Caldarelli M, Massimi L, Di Rocco C| title=Survival following treatment for intracranial ependymoma: a review. | journal=Childs Nerv Syst | year= 2009 | volume= 25 | issue= 10 | pages= 1303-12 | pmid=19387655 | doi=10.1007/s00381-009-0874-y | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19387655  }} </ref>
*Younger age at diagnosis.<ref name="pmid19387655">{{cite journal| author=Tamburrini G, D'Ercole M, Pettorini BL, Caldarelli M, Massimi L, Di Rocco C| title=Survival following treatment for intracranial ependymoma: a review. | journal=Childs Nerv Syst | year= 2009 | volume= 25 | issue= 10 | pages= 1303-12 | pmid=19387655 | doi=10.1007/s00381-009-0874-y | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19387655  }} </ref>
*[[Anaplastic|Anaplastic histology]].<ref name="pmid15022291">{{cite journal| author=Korshunov A, Golanov A, Sycheva R, Timirgaz V| title=The histologic grade is a main prognostic factor for patients with intracranial ependymomas treated in the microneurosurgical era: an analysis of 258 patients. | journal=Cancer | year= 2004 | volume= 100 | issue= 6 | pages= 1230-7 | pmid=15022291 | doi=10.1002/cncr.20075 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15022291  }} </ref>
*[[Anaplastic|Anaplastic histology]]<ref name="pmid15022291">{{cite journal| author=Korshunov A, Golanov A, Sycheva R, Timirgaz V| title=The histologic grade is a main prognostic factor for patients with intracranial ependymomas treated in the microneurosurgical era: an analysis of 258 patients. | journal=Cancer | year= 2004 | volume= 100 | issue= 6 | pages= 1230-7 | pmid=15022291 | doi=10.1002/cncr.20075 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15022291  }} </ref>
*Subtotal resection.<ref name="pmid1303-12">{{cite journal| author=White F| title=Epidemiology and infection control. | journal=Dimens Health Serv | year= 1975 | volume= 52 | issue= 12 | pages= 34, 37, 39 | pmid=1303-12 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1303  }} </ref>
*Subtotal resection<ref name="pmid1303-12">{{cite journal| author=White F| title=Epidemiology and infection control. | journal=Dimens Health Serv | year= 1975 | volume= 52 | issue= 12 | pages= 34, 37, 39 | pmid=1303-12 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1303  }} </ref>
*Lower doses of [[radiation]].<ref name="pmid22840355">{{cite journal| author=Vaidya K, Smee R, Williams JR| title=Prognostic factors and treatment options for paediatric ependymomas. | journal=J Clin Neurosci | year= 2012 | volume= 19 | issue= 9 | pages= 1228-35 | pmid=22840355 | doi=10.1016/j.jocn.2012.02.006 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22840355  }} </ref>
*Lower doses of [[radiation]]<ref name="pmid22840355">{{cite journal| author=Vaidya K, Smee R, Williams JR| title=Prognostic factors and treatment options for paediatric ependymomas. | journal=J Clin Neurosci | year= 2012 | volume= 19 | issue= 9 | pages= 1228-35 | pmid=22840355 | doi=10.1016/j.jocn.2012.02.006 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22840355  }} </ref>
*Immunohistochemical testing has identified increased expression of markers of proliferation (e.g., ''Ki-67'' and ''MIB-1'')<ref name="pmid15223962">{{cite journal| author=Wolfsberger S, Fischer I, Höftberger R, Birner P, Slavc I, Dieckmann K et al.| title=Ki-67 immunolabeling index is an accurate predictor of outcome in patients with intracranial ependymoma. | journal=Am J Surg Pathol | year= 2004 | volume= 28 | issue= 7 | pages= 914-20 | pmid=15223962 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15223962 }} </ref><ref name="pmid16342252">{{cite journal| author=Kurt E, Zheng PP, Hop WC, van der Weiden M, Bol M, van den Bent MJ et al.| title=Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas. | journal=Cancer | year= 2006 | volume= 106 | issue= 2 | pages= 388-95 | pmid=16342252 | doi=10.1002/cncr.21608 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16342252 }} </ref> and increased expression of ''[[EZH2]]'', a polycomb complex protein involved in epigenetic regulation of gene expression, as prognostic factors for greater risk of treatment failure.<ref name="pmid25586788">{{cite journal| author=Li AM, Dunham C, Tabori U, Carret AS, McNeely PD, Johnston D et al.| title=EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian Pediatric Brain Tumor Consortium study. | journal=Cancer | year= 2015 | volume= 121 | issue= 9 | pages= 1499-507 | pmid=25586788 | doi=10.1002/cncr.29198 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25586788 }} </ref>
*Immunohistochemical testing has identified increased expression of markers of proliferation (e.g., ''Ki-67'' and ''MIB-1'') and increased expression of ''[[EZH2]]'', a polycomb complex protein involved in epigenetic regulation of gene expression, as prognostic factors for greater risk of treatment failure.<ref name="pmid25586788">{{cite journal| author=Li AM, Dunham C, Tabori U, Carret AS, McNeely PD, Johnston D et al.| title=EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian Pediatric Brain Tumor Consortium study. | journal=Cancer | year= 2015 | volume= 121 | issue= 9 | pages= 1499-507 | pmid=25586788 | doi=10.1002/cncr.29198 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25586788 }} </ref><ref name="pmid15223962">{{cite journal| author=Wolfsberger S, Fischer I, Höftberger R, Birner P, Slavc I, Dieckmann K et al.| title=Ki-67 immunolabeling index is an accurate predictor of outcome in patients with intracranial ependymoma. | journal=Am J Surg Pathol | year= 2004 | volume= 28 | issue= 7 | pages= 914-20 | pmid=15223962 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15223962 }} </ref><ref name="pmid16342252">{{cite journal| author=Kurt E, Zheng PP, Hop WC, van der Weiden M, Bol M, van den Bent MJ et al.| title=Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas. | journal=Cancer | year= 2006 | volume= 106 | issue= 2 | pages= 388-95 | pmid=16342252 | doi=10.1002/cncr.21608 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16342252 }} </ref>


==References==
==References==
Line 35: Line 35:
{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Neurology]]
[[Category:Neurosurgery]]

Latest revision as of 22:19, 26 November 2017

Ependymoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Epidemiology and Demographics

Risk Factors

Differentiating Ependymoma from other Diseases

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Staging

Laboratory Findings

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Ependymoma natural history On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Ependymoma natural history

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Ependymoma natural history

CDC on Ependymoma natural history

Ependymoma natural history in the news

Blogs on Ependymoma natural history

Directions to Hospitals Treating Ependymoma

Risk calculators and risk factors for Ependymoma natural history

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2]

Overview

If left untreated, patients with ependymoma may progress to develop nausea, vomiting, headache, and irritability. Common complications of ependymoma include seizure, hydrocephalus, muscle paralysis, and speech problems.

Complication

Common complications associated with ependymomas are:

Prognosis

Unfavorable factors affecting outcome include the following:[1]

  • Gain of chromosome 1q25 is present in approximately 20% of pediatric intracranial ependymoma cases and has been reported as a negative prognostic factor by multiple research groups.[2][3]
  • Gene expression profile[4]
  • Other factors that have been reported to be associated with poor prognosis for pediatric ependymoma include expression of the enzymatic subunit of telomerase (hTERT) and expression of the neural stem cell marker Nestin.[5][6]
  • Tumor location. Cranial variants of ependymoma have a less favorable outcome than primary spinal cord ependymomas. Location within the spinal cord may also affect outcome, with tumors in the lower portion of the spinal cord having a worse prognosis.[7]
  • Younger age at diagnosis.[8]
  • Anaplastic histology[9]
  • Subtotal resection[10]
  • Lower doses of radiation[11]
  • Immunohistochemical testing has identified increased expression of markers of proliferation (e.g., Ki-67 and MIB-1) and increased expression of EZH2, a polycomb complex protein involved in epigenetic regulation of gene expression, as prognostic factors for greater risk of treatment failure.[12][13][14]

References

  1. ↑ Eoendymoma. http://www.cancer.gov/types/brain/hp/child-ependymoma-treatment-pdq#section/_35 URL Accessed on 10 6 2015.
  2. ↑ Godfraind C, Kaczmarska JM, Kocak M, Dalton J, Wright KD, Sanford RA; et al. (2012). "Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas". Acta Neuropathol. 124 (2): 247–57. doi:10.1007/s00401-012-0981-9. PMC 3554251. PMID 22526017.
  3. ↑ Mendrzyk F, Korshunov A, Benner A, Toedt G, Pfister S, Radlwimmer B; et al. (2006). "Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma". Clin Cancer Res. 12 (7 Pt 1): 2070–9. doi:10.1158/1078-0432.CCR-05-2363. PMID 16609018.
  4. ↑ Wani K, Armstrong TS, Vera-Bolanos E, Raghunathan A, Ellison D, Gilbertson R; et al. (2012). "A prognostic gene expression signature in infratentorial ependymoma". Acta Neuropathol. 123 (5): 727–38. doi:10.1007/s00401-012-0941-4. PMC 4013829. PMID 22322993.
  5. ↑ Tabori U, Ma J, Carter M, Zielenska M, Rutka J, Bouffet E; et al. (2006). "Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma". J Clin Oncol. 24 (10): 1522–8. doi:10.1200/JCO.2005.04.2127. PMID 16575002.
  6. ↑ Modena P, Buttarelli FR, Miceli R, Piccinin E, Baldi C, Antonelli M; et al. (2012). "Predictors of outcome in an AIEOP series of childhood ependymomas: a multifactorial analysis". Neuro Oncol. 14 (11): 1346–56. doi:10.1093/neuonc/nos245. PMC 3480268. PMID 23076205.
  7. ↑ Oh MC, Sayegh ET, Safaee M, Sun MZ, Kaur G, Kim JM; et al. (2013). "Prognosis by tumor location for pediatric spinal cord ependymomas". J Neurosurg Pediatr. 11 (3): 282–8. doi:10.3171/2012.11.PEDS12292. PMID 23259510.
  8. ↑ Tamburrini G, D'Ercole M, Pettorini BL, Caldarelli M, Massimi L, Di Rocco C (2009). "Survival following treatment for intracranial ependymoma: a review". Childs Nerv Syst. 25 (10): 1303–12. doi:10.1007/s00381-009-0874-y. PMID 19387655.
  9. ↑ Korshunov A, Golanov A, Sycheva R, Timirgaz V (2004). "The histologic grade is a main prognostic factor for patients with intracranial ependymomas treated in the microneurosurgical era: an analysis of 258 patients". Cancer. 100 (6): 1230–7. doi:10.1002/cncr.20075. PMID 15022291.
  10. ↑ White F (1975). "Epidemiology and infection control". Dimens Health Serv. 52 (12): 34, 37, 39. PMID 1303-12 Check |pmid= value (help).
  11. ↑ Vaidya K, Smee R, Williams JR (2012). "Prognostic factors and treatment options for paediatric ependymomas". J Clin Neurosci. 19 (9): 1228–35. doi:10.1016/j.jocn.2012.02.006. PMID 22840355.
  12. ↑ Li AM, Dunham C, Tabori U, Carret AS, McNeely PD, Johnston D; et al. (2015). "EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian Pediatric Brain Tumor Consortium study". Cancer. 121 (9): 1499–507. doi:10.1002/cncr.29198. PMID 25586788.
  13. ↑ Wolfsberger S, Fischer I, Höftberger R, Birner P, Slavc I, Dieckmann K; et al. (2004). "Ki-67 immunolabeling index is an accurate predictor of outcome in patients with intracranial ependymoma". Am J Surg Pathol. 28 (7): 914–20. PMID 15223962.
  14. ↑ Kurt E, Zheng PP, Hop WC, van der Weiden M, Bol M, van den Bent MJ; et al. (2006). "Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas". Cancer. 106 (2): 388–95. doi:10.1002/cncr.21608. PMID 16342252.

Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Ependymoma_natural_history&oldid=1393435"